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Overcoming cancer multidrug resistance through
inhibition of microparticles
Sora Vysotski, Rivka Winzelberg, and Dr. Mariana Babayeva

Touro College of Pharmacy, 230 West 125th St,
New York, NY 10027
plasma membranes [8]. When a cancer cell has a large
number of efflux transporters on its surface,
chemotherapeutic agents get pumped out of the cell before
they can harm the cell [9]. Thus, the malignant cells are
rendered resistant to chemotherapeutic agents. Most studied
efflux transporters essential in the resistance mechanism are
those of ABC protein super family: P- glycoprotein (P-gp)
and the Multidrug Resistance- Associated Protein 1 (MRP-1)
[10].

Abstract- One of the main obstacles to success of chemotherapy
agents is the development of cancer resistance. Cancer multidrug resistance (MDR) is thought to arise from over-expression
of efflux transporters on cancer cells’ plasma membranes.
Recently, microparticles (MP) were found to play a major role
in mediating the resistance to antineoplastic agents.
Microparticles can confer MDR phenotype to cancer cells
though 3 complimentary pathways: 1) Intercellular transfer of
P-gp and MRP1; 2) Intercellular transfer of regulatory nucleic
acids that ensure acquisition of MDR phenotype; and 3)
Internal sequestration of anticancer drugs to reduce the
amount of free active drug. Compounds that inhibit MP
formation that are currently under investigation include
calpain inhibitors, RhoA inhibitors, ROCK inhibitors, calcium
channel blockers, pantethine, glutaminase inhibitors, some
anti-platelet drugs and some lipid-lowering agents. This area of
research requires further development to select, improve and
test those compounds that show the most promise in providing
safe and effective treatment against MDR.
Keywords: cancer,
microparticles

multidrug

I.

resistance,

P-gp is a 170-kDa phosphoglycoprotein which derives
energy from hydrolysis of an ATP molecule in order to efflux
chemical compounds from the inside of a cell [11]. Its
physiological function is to protect both individual cells and
the organism as a whole from toxic elements [12, 13]. P-gp
substrates are usually hydrophobic organic compounds of
large molecular weight (>400g/mol) that carry a positive
charge at regular human blood pH [14]. Typical anticancer
drugs that are P-gp substrates are anthracyclines, vinca
alkaloids and taxanes [15].

chemotherapy,

MRP1 is a 190 kDa transporter protein that is very
similar to P-gp in its function. Even though there is a
significant overlap in MRP1 and P-gp substrates, MRP1 is
also able to efflux many other kinds of substrates including
hydrophilic compounds, glutathione, glucuronide conjugates
organic anions and heavy metals [16]. Therefore, MRP1
confers resistance to a broad range of other antineoplastic
agents such as methotrexate, etoposide, irinotecan,
mitoxantron, antiandrogens and even tyrosine kinase
inhibitors [17, 18].

INTRODUCTION

Cancer kills millions of people worldwide every year.
According to World Health Organization, cancer was a cause
of death for 8.2 million people in 2012. Annual cancer rates
are rising every year – from 14 million in 2012 to an
estimated 22 million in 2030 [1].
One of the main obstacles to success of chemotherapy
agents is the development of cancer resistance [2]. There are
many mechanisms that contribute to cancer resistance,
including mutated expression of drug targets [3], alterations
in apoptosis and repair mechanisms [4], reduced drug
uptake, increased drug efflux and enzymatic inactivation of
drugs [5]. Furthermore, many cancer cells display resistance
not only to a single chemotherapeutic agent, but also to a
range of structurally unrelated compounds [6]. The
phenomenon of resistance to several classes of unrelated
agents is termed Multi-Drug Resistance (MDR). MDR is
believed to be a contributing factor in 90% of treatment
failures in patients with metastatic cancer [7].

There are two types of tumor resistance: intrinsic and
acquired. Intrinsic resistance is usually seen in tumors rising
from organs that naturally have numerous efflux pumps such
as the intestines, kidneys, adrenal glands, liver, pancreas,
brain and lungs [19, 20]. These types of cancers are usually
resistant even to the first round of chemotherapy [21].
However, other cancers were shown to be able to acquire the
resistant phenotype after exposure to a single
chemotherapeutic agent [22]. Statistically, more than 50% of
cancer patients end up with the acquired MDR cancers and
experience cancer relapse [23]. Five year survival for
patients with ovarian cancer is about 30% despite surgical
interventions and potent chemotherapy because of the high
incidence of acquired MDR [24].

Cancer multi-drug resistance is thought to arise from
over-expression of efflux transporters on cancer cells’
DOI: 10.5176/2345-7201_1.4.32
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Intercellular transfer of P-gp through MPs was first
reported by Bebawy et al [41]. They observed drug sensitive
leukemia cells (CCRF-CEM) acquired functional P-gp after
exposure to MPs shed from drug resistant leukemia cells in
as little as 4 hours. Likewise, functional MRP1 was detected
after 12 hours of co-culture of MPs and drug-sensitive
leukemia cells in vitro [42]. An in vivo experiment done on
murine tumor xenograph models (MCF-7) also demonstrated
ability of MPs to transfer MDR to recipient cells. P-gp loaded
MPs were injected subcutaneously near the tumors. In about
24 hours, P-gp could be detected in the recipient tumor cells,
and acquired MDR phenotype remained stable for at least
two weeks [43].

Since the discovery of the strong link between MDR and
efflux transporters, the main strategy in circumventing MDR
was the development of efflux pump inhibitors. However,
this method has not yet proven viable in a clinical setting
because of dose- limiting toxicities and failure to
demonstrate survival advantage. Inhibition of efflux
transporters led to greater blood brain barrier permeability
and caused severe neurologic side effects [25]. Furthermore,
past research involved only either P-gp inhibitors or MRP1
inhibitors. Given the substrate redundancy of P-gp and
MRP1 transporters, if one is inhibited, the other one may still
confer resistance to cancer cells. Therefore, current drug
discovery focuses on identifying and studying compounds
that inhibit both P-gp and MRP1 simultaneously. No such
compounds have yet been discovered. A potent P-gp and
MRP inhibitor, VX-710, showed positive results in vitro
[26]. However, during Phase II clinical trial only 7 out of 36
patients treated with VX-710 had even a partial response
[27]. Currently researchers are investigating other strategies
that would overcome MDR with greater efficacy.

Acquisition and incorporation of MDR phenotype is also
mediated by MPs transfer of regulatory nucleic acids.
Especially of interest are microRNAs (miRNAs). MiRNAs
are a class of endogenous single stranded non-coding
regulatory RNAs that are typically 19-25 nucleotides in
length [44]. They modulate activity of specific mRNA
targets and regulate protein synthesis [45]. MiRNAs have
been shown to significantly affect cellular mechanisms
including proliferation, metabolism, apoptosis and resistance
to chemotherapeutic agents [46]. Changes in miRNA
expression were linked to drug resistance of some common
antineoplastics including topotecan, doxorubicin, cisplatin,
and methotrexate [47, 48]. Furthermore, recent studies had
identified specific miRNAs directly associated with MDR in
cancer. For example, miR-27a and miR-451 expression were
shown to activate MDR1/P-gp expression in resistant human
ovarian cells [49]. Similarly, overexpression of miR-21 and
downregulation of the PDCD4 (tumor suppressor protein)
were demonstrated to upregulate the number of P-gp
expressing breast cancer cells and induce chemoresistance
[50]. In addition, miR-297 was also recently found to play a
role in development of MDR by modulating MRP expression
in colorectal tumors [51]. These studies suggest that
miRNAs transferred by MPs from drug resistant to drug
sensitive cells are able to transform transcriptional landscape
and ensure acquisition of MDR phenotype in the recipient
cells by regulating mRNA expression.

In the past, scientists thought that cancer cells were able
to acquire the resistant phenotype and over-express efflux
transporters only through various genetic and epigenetic
changes [28, 29]. Modulation of P-gp and MRP1 expression
was reported to be a consequence of increased mRNA
stability, gene transcription and gene amplification [30, 31],
as well as upregulation of oncogenes and downregulation of
tumor suppressor genes [32]. However, recent research
proposed and substantiated the idea of non-genetic
intercellular transfer of proteins mediated by so called,
microparticles [33].
Microparticles (MPs) are small vesicles that are released
from the surface of cells by the process of outward
membrane budding [34]. They usually express
phosphatidylserine (PS) on their outer layer and are about 0.1
to 1 micrometers in diameter [35]. In the past they were
considered insignificant blebs that did not have any
important function in the body [36]. However, according to
the recent research, MPs play an essential role in many
physiological
functions
including
intercellular
communication, inflammation, coagulation, vascular
homeostasis and oncogenic transformation [37, 38]. MPs
levels are elevated in many disease states including
atherosclerosis, cerebral malaria, HIV, sepsis, different
autoimmune disorders and cancer [39], suggesting their role
in pathogenesis and a possible therapeutic target.
MPs act as cellular messengers transferring their content
short and long distance to recipient cells. MPs can carry
diverse types of cargo including cellular proteins (such as
efflux transporters), second messengers, cytokines, integrins,
transcription factors, and genetic material from their cells of
origin [40].

Lastly, MPs are also able to sequester drugs within their
intravesicular space, which leads to reduced amount of free
flowing drug available for anti-tumor action. After MPs were
exposed to daunorubicin and doxorubicin, the remaining free
drug concentrations were measured using fluorescence
analysis and degrees of sequestration were calculated. For
drug sensitive MPs degrees of sequestration were 22 and 38
a.u. for daunorubicin and doxorubicin respectively, and for
drug resistant MPs - 5 and 4 a.u., respectively. Furthermore,
using imaging techniques authors found that drug resistant
MPs carried some P-gp transporters in inside-out orientation
on their surface. Thus, P-gp acted as influx pumps and helped
MPs sequester antineoplastic agents [52].

MPs can confer MDR phenotype to cancer cells though 3
complimentary pathways: 1) Intercellular transfer of P-gp
and MRP1; 2) Intercellular transfer of regulatory nucleic
acids that ensure acquisition of MDR phenotype; and 3)
Internal sequestration of anticancer drugs to reduce the
amount of free active drug.

Recent studies have demonstrated that MPs are elevated
in many cancer types including breast [53], gastric [54] and
pancreatic [55]. MPs were found to play a critical role not
only in cancer drug resistance but in many other aspects of
tumor aggressiveness including development of metastases
(by transfer of miRNA and matrix degrading proteinases)
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[56], angiogenesis (by the dissemination of VEGF) [57, 58],
improved cellular survival (by the removal of cytosolic
caspase 3) [59] and avoidance of immune surveillance (via
expression of LMP-1 and Fas ligand) [60]. Therefore, a
growing body of research is focusing on inhibiting cancer
microparticle formation [61].

III.

A. Is it safe to inhibit microparticles?
Currently, not everything is known about MP functions in
the body, therefore it is difficult to assess safety of
microparticle inhibitors in clinical studies. There is a very
rare autosomal human disease, called Scott Syndrome, which
is characterized by lack of MP formation and impaired
thrombin generation resulting in severe bleeding. However,
bleeding was not reported to be a side effect in animal
models that were given microparticle inhibitors [75].
Moreover, MPs were shown to induce generation of both
thrombin [76] and plasmin [77]. Therefore, it is not clear if
inhibition of MPs leads to coagulation imbalances or not. In
any way, all MP inhibitors available to date do not suppress
MP formation completely; and therefore, should not cause
serious side effects.

This review will focus on elucidation of MPs biogenesis
and enumeration of novel inhibitors of MPs formation that
may become effective treatments against cancer multidrug
resistance.

II.

INHIBITION OF MICROPARTICLES FORMATION

FORMATION OF MICROPARTICLES

Microparticles are produced by an unusual mechanism
that does not require the help of endoplasmic reticulum and
Golgi apparatus [62]. Currently, it is thought that
microparticles are released from a cell upon cellular
activation or apoptosis after disruption of phospholipid
asymmetry when PS (that is usually found on the surface of
MPs) is redistributed from the inner leaflet of the plasma
membrane to the outer leaflet [63]. Cellular activationinduced MP release is associated with the activity of calpains
[64], while apoptosis-induced MP formation is regulated by
the Rho family of small GTPases [65].

Since MPs play a central role in MDR development
and in other manifestations of cancer aggressiveness, much
research has been done to identify compounds that may
inhibit or modulate MP biogenesis or release from tumor
cells. These include calpain inhibitors, RhoA inhibitors,
ROCK inhibitors, calcium channel blockers, pantethine,
glutaminase inhibitors, some anti-platelet drugs and some
lipid-lowering agents.

Calpains are calcium-activated cysteine proteinases that
are involved in proteolysis, cytoskeletal remodeling, cell
motility and apoptosis [66]. There are currently 14 known
human calpain isoform genes [67]. The two well-studied
members are mu-calpain and m-calpain which differ in their
catalytic subunit called calpain-1 and calpain-2, respectively
[68]. When a cell is activated, intracellular calcium
concentration rises and activates calpain, which hydrolyses
the actin binding proteins and disrupts the cytoskeleton
immediately under the phospholipid bilayer. These structural
changes facilitate microparticle membrane budding [69].

B.

Calpain Inhibitors
Calpains are required for MP formation. Increased
expression of calpain was observed in several cancer types
including schwannomas, meningiomas, renal cell carcinomas
and colorectal adenocarcinomas [78, 79, 80]. It has been
speculated that inhibiting calpain may prevent microparticle
release into the bloodstream and reduce the incidence of
acquired MDR. There are several studies showing that
calpain inhibitors can decrease the amount of circulating
MPs and increase sensitivity of different tumors to multiple
structurally unrelated anti-cancer drugs.

The Rho family of small GTPases, including RhoA, Rac
and Cdc42, regulates actin cytoskeleton organization and
dynamics [70]. These molecules play a significant role in
formation of stress fibers and their signaling pathways affect
gene expression and cell survival [71]. Recently, they were
also shown to be key regulators of microparticle formation
and shedding [72]. RhoA, Rac and Cdc42 are mutated or
overexpressed in many kinds of resistant cancers, suggesting
their involvement in MDR [73]. The downstream signaling
pathway of Rho A that induces MP formation includes Rhoassociated coiled-coil containing protein kinase (ROCK),
LIM kinase (LIMK) and Cofilin [74]. During apoptosis when
cytoskeletal rearrangements occur, activated caspases
(enzymes associated with apoptosis) cleave ROCK which
fuels cellular transformation and production of MPs [74].

Calpastatin is an endogenous inhibitor of calpains [81].
Following calcium influx, calpastatin is released into the
cytosol and reversibly inhibits up to four molecules of
calpain at once by blocking calpain’s active sites [82].
Calpastatin serves as a structural and functional template in
the development of novel calpain inhibitors. Most calpain
inhibitors available to date target the thiol- containing active
site of the calpain. They display limited selectivity to
calpains and are often vulnerable to rapid degradation by
proteinases in vivo [83]. Structure-activity relationship
(SAR) studies have fixed pharmacokinetic properties of
calpain inhibitors but they were not successful in refining
their selectivity [84]. Other calpain inhibitors that target
calpain’s allosteric site have demonstrated higher selectivity
to calpain and are currently under investigation [85].
One calpain inhibitor, MDL-28170, has been shown to
significantly reduce MP release from activated platelets [86].
Similarly, another calpain inhibitor, Calpeptin, has been
shown to reduce the formation of MPs from activated
platelets by about 70% [87]. Moreover, these two calpain
inhibitors, Calpeptin and MDL28170, were shown to
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increase sensitivity of HER2 positive breast cancer cells to
Trastuzumab, a HER2 monoclonal antibody. Skbr3 cells
were spread on fibronectin in the presence of Trastuzumab
alone as a control or along with each calpain inhibitor.
Inclusion of each inhibitor increased cells sensitivity to
Trastuzumab by more than 15% (P<0.01) [88].

Inhibition of ROCK with Y-27632 compound reduced
MP formation in human breast cancer cells by 25% [90].
Another study showed that Y-27632 almost completely
inhibited MP formation in various cancerous cell lines,
including HeLa cervical cancer cells, MDAMB231 breast
cancer cells, and U87 brain tumor cells [101].

In another experiment on human melanoma cells
allosteric calpain inhibitor, PD150606, combined with a
proteasome inhibitor, had significantly reduced viability of
cisplatin resistant tumor cells [89]. Furthermore, effect of
calpain inhibitors, PD- 150606 and ALLM, were studied in
drug resistant human breast adenocarcinoma cells. Both
inhibitors caused about 20% drop in MP production.
Interestingly, PD-150606 worked only on activated cells,
whereas ALLM showed an inhibitory effect on both
stimulated and unstimulated cancer cells [90].

Fasudil, initially approved in Japan for treatment of
cerebral vasospasms and pulmonary hypertension [102], is
the the only clinically available ROCK inhibitor. It has been
shown to suppress cancer migration, metastasis [103] and
angiogenesis [104]. Moreover, fasudil and another
Rho/ROCK inhibitor Y27632 were proven to enhance
efficacy of cisplatin. Treatment with cisplatin at 100 microM
together with fasudil or Y-27632 showed a synergistic
growth inhibitory effect in the cisplatin-resistant cell line. On
the other hand, in a cisplatin-sensitive cell line, cisplatin in
combination with ROCK inhibitors had similar effects as
cisplatin alone. An explanation for the difference in response
lies in the understanding of microparticle-mediated drug
resistance [105]. ROCK inhibitors increase cisplatin efficacy
in cisplatin resistant cell lines because they inhibit
microparticle formation, suppressing the transfer of drug
resistance and malignant miRNAs between the cells.

C. Inhibitors of Rho-A, Rac, Cdc42 and their downstream
effectors
Rho-A, Rac, Cdc42 and their downstream effectors
(LIMK and ROCK) are also essential players in MP
biogenesis. Blocking or limiting their function prevents
production of MPs and reduces cancer resistance and
aggressiveness. Knockout of Rho-A expression using
adenovirus-mediated
RNA
interference
inhibited
microparticle biogenesis in cervical carcinoma HeLa cells
[72]. Similar experiments in lung [91], colorectal [92] and
ovarian [93] cancer cells showed that Rho-A knockout
decreased proliferation, migration and metastasis of cancer
cells, all functions that are associated with MPs. Likewise,
AZA1 which inhibits both Rac1 and Cdc42 but not RhoA
was found to suppress prostate cell migration and growth
[94].

One of the newest ROCK inhibitors with improved
selectivity and potency, AT13148, which has shown
promising results in animal studies, has recently entered
Phase I clinical trial for advanced solid tumors [99].

D. Calcium Channel Blockers (CCBs)
Increase in intracellular calcium concentration initiates
calpain activity and results in MPs formation. Therefore, it
has been hypothesized that CCBs are able to decrease
amount of MPs in body circulation.

A recent study on breast cancer cell lines revealed that
microparticle-mediated acquisition of MDR is closely linked
to enhanced metastatic capacity of the recipient cancer cells.
As shown in the experiment, when highly metastatic, drug
resistant cells were co-cultured with lowly metastatic drugsensitive cells, the latter ones acquired MDR and an
increased metastatic capacity [95]. Putting these studies
together reveals that MPs are the source of both metastasis
and cancer resistance; and therefore, these compounds that
suppress metastasis are possibly also suppressing
microparticles and MDR.

In one experiment, diabetes patients were given
benidipine, a dihydropyridine CCB, for 6 months. At the end
of therapy, their MP levels were found to be significantly
lower than in the beginning [106, 75]. Likewise, in another
study, the CCB nifedipine was shown to reduce platelet MPs
by about 50 % in patients with transient ischemic attacks
[107, 75].
However, in an in-vitro experiment, verapamil, a nondihydropyridine CCB, did not reduce the number of MPs
released from drug-resistant breast cancer cells. On the
contrary, verapamil showed a significant increase in MP
count relative to the control (by about 45%) [90].

Inhibitions of RhoA down-stream effectors, LIMK and
ROCK, were also successful in reducing MP production.
There is only one study showing that blockage of LIMK
expression by LIMK si-RNA inhibits microparticle
formation [72]. However, ROCK inhibitors have been
extensively studied for more than a decade. They have been
proven effective treatments for multiple disease states such
as glaucoma [96], ocular hypertension [97], erectile
dysfunction [98] and advanced solid tumors [99]. In cancer,
ROCK inhibitors were found to suppress tumor invasion,
metastasis and MDR [100].

There seems to be a controversy regarding the effect
of CCBs on microparticle formation. Perhaps, there is an
unknown
mechanism
that
differentiates
between
dihydropyridines and non-dihydropyridines influence on
MPs. Additionally, verapamil was already studied in clinical
trials as a P-gp inhibitor and failed to slow the progression of
cancer or decrease mortality rates because doses high enough
to possibly convey a survival advantage caused intolerable
cardiac side effects [108]. Further research is needed to
identify those CCBs that can effectively decrease MP levels
and not cause cardiac or other complications.
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significantly increased suggesting its role in suppression of
microparticle formation [115]. However, evidence regarding
the effect of other statins on MP production is mixed.
Atorvastatin decreased platelet derived MPs but increased
endothelial MPs [116], while simvastatin had no effect on
any microparticles in one study [117], but was found to
increase endothelial MPs in another study [118].

E. Pantethine
Pantethine is a dimer of a pantothenic acid linked by a
disulfide cystamine. It has been shown to inhibit the early
step of inflammation-coagulation cascade by blocking
translocation of phosphatidylserine (PS) [109]. Since
movement of PS is important in MP biogenesis, pantethine
was studied and was found to decrease MPs both in vitro and
in vivo.

EPA/DHA is also used as a lipid-lowering agent and
prophylaxis against cardiovascular events. In a 12-week
study, EPA/DHA daily use was associated with significantly
reduced levels of platelet-derived MPs [119]. Furthermore,
when EPA was combined with pitavastatin for a 6 month
period in diabetic patients; reduction in platelet-derived MPs
was significantly greater than EPA alone (50% vs 20%)
[120].

After incubation of 1 mM of pantethine with mouse brain
endothelial cells, the concentration of MPs was decreased by
51% [110, 75]. A similar experiment with pantethine and
human umbilical vein endothelial cells showed MP
production reduced by 24% compared to controls. In vivo,
malaria-infected mice that were treated with 30mg injections
of pantethine for 7 days had significantly lower levels of
circulating MPs (by about 50%) compared to control mice
that were also infected with malaria but were not treated with
pantethine. Interestingly, pantethine did not reduce MP
levels in mice not infected with malaria suggesting that
pantethine acts selectively on disease-promoting MPs and
does not have a negative influence on normal function of
MPs in the body [39]. The effect of pantethine on MP
formation was also recently studied in tumor cells. Pantethine
was incubated with activated drug resistant human breast
adenocarcinoma cells for 25 hours, and MP release was
quantified by flow cytometry. Pantethine reduced MP
formation by 24% relative to control [90].

H. Glutaminase inhibitors - BPTES and 968 compounds
Metabolism in cancer cells is slightly different from
metabolism in healthy human cells. Healthy human cells
usually convert pyruvate into citrate in mitochondria to make
ATP. Cancer cells, on the other hand, primarily convert
pyruvate into lactic acid, and increase glutamine metabolism
to produce alpha-ketoglutarate for entrance into citric acid
cycle [121].
Inhibition of glutaminase, an enzyme that catalyzes
glutamine transformation into glutamate, was found to inhibit
microparticle formation. In an experiment showing that
glutaminase activity is linked with microparticle biogenesis,
MDAMB23 breast cancer cells were treated with
glutaminase allosteric inhibitors, BPTES (bis-2-(5phenylacetamido-1,2,4-thiadiazol-2-yl) ethylsulfide) and 968
(bromo- dibenzophenathridine). After a two day period,
immunofluorescence analysis showed that untreated cells had
5 times more MP budding than BPTES and 968 treated cells
[72]. Thus, BPTES and 968 compounds warrant further
research as potential clinically useful inhibitors of
microparticle formation.

F.

Anti-platelet drugs – Ticlopidine and Clopidogrel
Ticlopidine and clopidogrel are anti-platelet agents used
for prevention of thrombosis after a heart attack, stroke, stent
placement or other similar conditions. These disease states
are associated with high MP levels [111]. Ticlopidine
(200mg/day) was shown to reduce MP levels in diabetic
patients by 20 to 30%. Nevertheless, even after use of
ticlopidine the numbers of MPs were still elevated compared
to healthy individuals [111, 75].
The effect of clopidogrel on MP formation was assessed
in 26 subjects with stable coronary artery disease. Amount of
circulating MPs was inversely correlated with clopidogrel Cmax and AUC [112]. In addition, in another recent study
clopidogrel was found to decrease accumulation of MPs at
the site of thrombosis and reduce tumor growth and
metastasis in mice with pancreatic cancer [113].

IV.

CONCLUSION

Overcoming cancer MDR is not an easy task.
Microparticle’s ability to confer MDR by sequestering
chemotherapeutic agents and transferring P-gp, MRP1 and
miRNA from one cell to another make MPs an excellent
target for circumvention of acquired cancer resistance. Many
compounds that inhibit MP formation have been identified
and are currently under investigation. This area of research
requires further development to select, improve and test those
compounds that show the most promise in providing safe and
effective treatment against MDR.

G.

Lipid-lowering agents – Statins and EPA/DHA
Statins are drugs of choice for prevention of
cardiovascular events. Statins inhibit cholesterol biosynthesis
in the liver, and they also have many pleiotropic effects on
vascular function including anti-inflammatory and antithrombotic effects [114]. Recently, rosuvastatin was reported
to influence the number of circulating microparticles. One
week after rosuvastatin discontinuation, microparticle levels
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